Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

Cena opens up about his experience living with Demodex blepharitis, a common eyelid disease caused by microscopic mites that live in and around ...
The American Journal of Managed Care

Managed Care Considerations in the Treatment of Demodex Blepharitis

AJMC®: Could you describe the current standard of care for Demodex blepharitis and how it has evolved? PERIMAN: The understanding and management of Demodex blepharitis have evolved quite a bit in ...
The American Journal of Managed Care

Cost-Effective Medication Access in Demodex Blepharitis Treatment

An expert provides insights into the cost of misdiagnosed Demodex blepharitis and payer considerations for a potential cost-effective treatment. This is a video synopsis/summary of an Insights ...
Monthly Prescribing Reference

Xdemvy Now Available for Demodex Blepharitis Treatment

Credit: Tarsus Pharmaceuticals. Xdemvy is supplied as an ophthalmic solution containing lotilaner 0.25% (2.5mg/mL) in a 10mL bottle. Xdemvy ™ (lotilaner ophthalmic solution) is now available for the ...

John Cena reveals the "parasite" diagnosis he ignored for years

John Cena opens up about his overlooked eye disease and the diagnosis that changed his approach to health.
Monthly Prescribing Reference

Xdemvy Approved for Treatment of Demodex Blepharitis

Credit: Tarsus Pharmaceuticals. Xdemvy is supplied as an ophthalmic solution containing lotilaner 0.25% (2.5mg/mL) in a 10mL bottle; it is expected to be available by the end of August 2023. The Food ...
Seeking Alpha

FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis

XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S. XDEMVY targets the root ...
MedPage Today

First Treatment for Demodex Blepharitis Wins FDA Approval

The FDA approved lotilaner ophthalmic solution 0.25% (Xdemvy) as the first specific treatment for Demodex blepharitis. Lotilaner (formerly TP-03) is an ectoparasiticide that targets Demodex mites, ...
Healio

BLOG: Now is the time to ramp up identification, treatment of Demodex blepharitis

Please provide your email address to receive an email when new articles are posted on . Demodex blepharitis is so common that it makes up more than two thirds of all blepharitis cases. In fact, nearly ...
Evansville Courier & Press

FDA-Approved Drop XDEMVY Offers Targeted Relief for Demodex Blepharitis Patients, Modern Vision Solutions Reports

Modern Vision Solutions has announced the publication of a new article, “Demodex Blepharitis Treatment in Omaha,” highlighting a significant shift in how optometrists approach the treatment of chronic ...
Healio

‘Mite Party’ campaign designed to educate consumers about Demodex blepharitis

Please provide your email address to receive an email when new articles are posted on . The “Mite Party” campaign is designed to raise awareness about Demodex blepharitis. Tarsus launched the campaign ...